Navigation Links
Ground-breaking Research Identifies Molecular Subtyping as a Key to Determining Prognosis and Benefit of Chemotherapy for Breast and Colorectal Cancers
Date:5/31/2013

IRVINE, Calif., May 31, 2013 /PRNewswire/ -- Agendia, a world leader in molecular cancer diagnostics, today announced that results from five studies focused on breast, colon and colorectal cancer will be presented at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting to be held May 31-June 4, 2013 at McCormick Place in Chicago. Of particular importance are the studies which demonstrate that molecular subtyping allows for improvement in therapy selection and overall patient survival. 

The posters covering breast cancer include:

  • Effectiveness of MammaPrint® and BluePrint® in identifying molecular subtypes of breast tumors as a predictor for tumor response to targeted chemotherapies.
  • MammaPrint MINT study assesses the ability of molecular profiling and traditional pathologic and clinical prognostic factors to predict patient response to neo-adjuvant chemotherapy.
  • Genomic profiling of breast cancer in African American women.

"It is clear that molecular subtypes are key pieces of information in determining the best course of treatment for breast cancer patients, and that subtyping will only become more important as hundreds of targeted therapies reach the market in the coming decade," said Agendia CEO David Macdonald .

The posters/discussions covering colorectal and colon cancer include:

  • Intrinsic subtypes of colorectal cancer that direct different treatment strategies.
  • The use of ColoPrint® as a predictor of outcome and chemotherapy benefit in stage II and III colon cancer patients.

"Like breast cancer, where molecular classification into subtypes has clear relevance for prognosis and treatment, we are finding clinically relevant subtypes for colorectal and colon cancer," Macdonald added. "Agendia has a rich history of presenting innovative and ground-breaking research that benefits oncologists and their cancer patients."

A more complete list of presentation abstracts can be found on ASCO's website at www.asco.org.

About Agendia:
Agendia is a leading molecular diagnostic company that develops and markets FFPE-based genomic diagnostic products. Agendia's breast cancer Symphony suite was developed by analyzing the complete human genome, ensuring 100% definitive results for cancer patients. Together, these tests help physicians determine a patient's individual risk for metastasis, which patients will benefit from chemo, hormonal, or combination therapy, and which patients do not require these treatments and can instead be treated with other less arduous and less costly methods.

In addition to the Symphony suite of tests, Agendia has a rich pipeline of genomic products in development. The Company collaborates with pharmaceutical companies, leading cancer centers and academic groups to develop companion diagnostic tests in the area of oncology and is a critical partner in the ISPY-2 and MINDACT trials.  For more information, please visit www.agendia.com.


'/>"/>
SOURCE Agendia
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Convergence Pharmaceuticals Announces Successful Interim Data from Ground-Breaking Phase II Trigeminal Neuralgia Study
2. Lilly Statement on Indiana Biosciences Research Institute
3. Breast Cancer Imaging Market: US, EU, South America Analysis & Forecast Research Reports
4. New Research Shows Continuing Medical Education Saves Healthcare Costs
5. Alzheimer Market: Drugs, Therapeutics & Diagnostics Research Reports
6. Cempra Awarded $58 Million Contract to Develop Antibiotic for Pediatric Use and Biodefense by Biomedical Advanced Research and Development Authority (BARDA)
7. International Mesothelioma Experts Present Promising New Research Findings at the 3rd Annual International Symposium on Lung-Sparing Therapies for Malignant Pleural Mesothelioma
8. Clinical Team Researching the Impact of the EarlySense System Wins Best Novel Idea Prize at the Rapid Response Systems and Medical Emergency Teams 2013 8th International Conference
9. Lupus Research Institute Hosts First International Conference to Advance New Treatments for Lupus Nephritis
10. Research-based Pharmaceutical Industry Launches Do You Mind? Campaign to Fight Mental and Neurological Disorders
11. Claret Medical, Inc. Announces Publication of the First Clinical Research on the Frequency and Composition of Embolic Debris Captured during TAVR
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2017)... Oct. 5, 2017  In response to the ... and Maxillofacial Surgeons (AAOMS) released prescribing recommendations that ... be used as a first-line therapy to manage ... Recognizing the value and ... Paper "Opioid Prescribing: Acute and Postoperative Pain Management" ...
(Date:10/4/2017)... , Oct. 4, 2017 OBP ... self-contained, illuminating medical devices, today announced regulatory approval ... Surveillance Agency (or Agência Nacional de Vigilância Sanitária ... single-use, cordless surgical retractor with integrated LED light ... access, illumination and exposure of a tissue pocket ...
(Date:10/2/2017)... 2017  AllianceRx Walgreens Prime, the combined central specialty ... pharmacy benefit manager Prime Therapeutics LLC (Prime), today officially ... the unveiling of new signage at its headquarters in ... at a few other company-owned facilities across the country. ... some of whom will begin to see the AllianceRx ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... “America On The Brink”: the Christian history of the ... is the creation of published author, William Nowers. Captain Nowers and his wife, ... he spent thirty years in the Navy. Following his career as a naval ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
(Date:10/12/2017)... ... ... On Saturday, October 21, the Health & Wellness Center at Florida Hospital ... for the American Heart Association Heart Walk. Teams of up to 10 people can ... their treadmills moving for 5 hours. Treadmills will start at 7:00 p.m. on Saturday, ...
(Date:10/12/2017)... FL (PRWEB) , ... October 12, 2017 , ... ... presenting the latest in wound care advancements to physician colleagues, skilled nursing facility ... is titled, "Navigating the Treacherous Waters of Wound Care." , "At many of ...
Breaking Medicine News(10 mins):